Product Name | Encapsulated Drugs | Type of Liposomes | Indications | Lipid Composition | Particle Size | Status | Reference |
---|---|---|---|---|---|---|---|
nm | |||||||
CPX-351 | Cytarabine and daunorubicin (5:1) | Bilamellar liposomes | Acute myeloid leukemia | DSPC, DSPG and cholesterol | 100 | Phase III | NCT01696084a (accessed on Apr 14, 2015); Feldman et al. (2011); Cortes et al. (2015) |
Lipoplatin | Cisplatin | PEGylated liposomes | NSCLC, gastric, pancreatic, breast, head and neck cancers | PC, cholesterol, DPPG, DSPE-PEG2000Da | 110 | Phase III | Boulikas (2009); Stathopoulos et al. (2010) |
MM-398 (PEP02) | Irinotecan | PEGylated liposomes | Metastatic pancreatic cancer | DSPC, DSPE-PEG2000Da, cholesterol | 100-110 | Phase III | NCT01494506a (accessed on Apr 15, 2015); Drummond et al. (2006); Kang et al. (2015); Roy et al. (2013); Saif (2014) |
Thermodox | Doxorubicin | Lyso-lipid temperature sensitive liposomes | Hepatocellular carcinoma and breast cancer | DPPC, MSPC, DSPE-PEG2000Da | 175 | Phase III | NCT00617981a (accessed on Apr 15, 2015); May and Li (2013) |
↵a ClinicalTrials.gov identifier
DPPC, 1,2-dipalmitoyl phosphatidylcholine; DPPG, 1,2-dipalmitoyl phosphatidylglycerol; MSPC, mono-stearoyl phosphatidylcholine; NSCLC, non-small cell lung cancer